Basaglar KwikPen

Insulin glargine

DM in adults, adolescents & childn ≥2 yr.

SC Individualized dosage. Administer once daily at any time but at the same time each day. Type 2 DM Can also be given together w/ orally active antidiabetics. Switch from bid NPH insulin Reduce daily dose by 20-30% during the 1st wk of treatment. Switch from insulin glargine 300 u/mL Reduce dose by approx 20%.

Hypersensitivity.

Should not be administered IV. Not the insulin of choice for diabetic ketoacidosis. Intensified blood glucose monitoring in patients w/ clinically relevant hypoglycemic episodes eg, significant stenoses of the coronary arteries or of the blood vessels supplying the brain (risk of cardiac & cerebral complications) & w/ proliferative retinopathy particularly if not treated w/ photocoagulation (risk of transient amaurosis). Severe hypoglycemia. Intensified metabolic monitoring is required for intercurrent illness. Observe for signs & symptoms of heart failure, wt gain & edema if used in combination w/ pioglitazone; discontinue pioglitazone if any deterioration in cardiac symptoms occurs. Instruct patients to perform continuous rotation of the inj site to reduce the risk of developing lipodystrophy & cutaneous amyloidosis. Monitor blood glucose after the change in the inj site & consider dose adjustment of antidiabetics. May cause insulin Ab to form. May impair ability to drive & operate machinery. Renal & hepatic impairment. Pregnancy & lactation. Childn <2 yr. Elderly ≥65 yr.

Hypoglycemia. Lipohypertrophy; inj site reactions.

May enhance blood-glucose-lowering effect & increase susceptibility to hypoglycemia w/ oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, somatostatin analogues & sulphonamides. May reduce blood-glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, estrogens, progestogens, phenothiazine derivatives, somatropin, sympathomimetics [eg, epinephrine (adrenaline), salbutamol, terbutaline], thyroid hormones, atypical antipsychotics (eg, clozapine & olanzapine) & PIs. May either potentiate or weaken blood-glucose lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. May reduce adrenergic counter-regulation signs w/ β-blockers, clonidine, guanethidine & reserpine.

Insulin Preparations

A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

Rx